Abstract：
Combination therapies of an immune checkpoint inhibitor and a molecular targeted agent are widely accepted as an appropriate initial systemic therapy for metastatic renal cell carcinoma (RCC), but there is little published evidence regarding the efficacy of this approach in patients with end-stage renal disease (ESRD). Here, we report three patients who were undergoing hemodialysis for ESRD whose metastatic RCC was successfully treated using avelumab plus axitinib. The patients were a 67-year-old man with swollen lymph nodes, a 65-year-old man with pleural dissemination, and a 71-year-old man with lung nodules and an infra-diaphragmatic nodule. They were administered a combination of avelumab plus axitinib as their initial systemic therapy following definitive surgical therapy. The best response of three patients was graded as partial response. No severe adverse events were identified. This is the first report of the use of combination therapy consisting of avelumab plus axitinib in patients with ESRD undergoing hemodialysis. We found that this combination was useful in such patients.
摘要：
免疫检查点抑制剂和分子靶向药物的联合治疗被广泛接受为转移性肾细胞癌（RCC）的合适的初始全身治疗。但关于这种方法在终末期肾病(ESRD)患者中的疗效,已发表的证据很少.这里,我们报告了3例接受ESRD血液透析的患者,其转移性RCC使用阿维鲁单抗联合阿西替尼成功治疗.病人是一名67岁的男子，淋巴结肿大，一名65岁的男性胸膜播散，一名71岁的男性，有肺结节和膈下结节。他们在明确的手术治疗后给予阿维鲁单抗加阿西替尼的组合作为他们的初始全身治疗。三名患者的最佳反应被分级为部分反应。未发现严重不良事件。这是关于在进行血液透析的ESRD患者中使用由avelumab加axitinib组成的联合疗法的第一份报告。我们发现这种组合对此类患者有用。
